RE:RE:Jfm will like this oneWhile I do not know any of the actual specifics in either protocol, it seems logical to me that TH management are well aware their NASH protocol faces some potential challenges but the cancer one should be relatively strightforward.
Again, we do not know everything that is going on at the company and what advantage it might be in some unrelated thing we could never know about for TH to not be more open about the protocol submissions. Or, it just might be they have nothing unique about these protocols which is keeping them from sharing the submission dates and it is simply the way they think it is best to handle such situations.
My best guess is they know they could get into a longer discussion with the FDA on the NASH protocol and they don't want us wondering where the news in when it went past 60 days from submission. And if they are not going to tell us about the NASH protocol, then they can't tell us about the cancer protocol - they at least have to be consistent.
In a market that eats up such press releases, however, it is a bit of a shame they chose not to PR these. I am assuming TH lived up to its commitment to get them filed befoer the end of 2020 but got no repsonse from IR when I asked about that. Maybe we will hear somethign about it soon.
They are on the agenda at a Wainwright conference in January and I imagine there may be other conferences coming up as well at which they may be part of. That will give them an opportunity to tell us something if they want to.
longterm56 wrote: It seems that other companies think it is important to have a press release upon submission of INDs ... I just don't get it. It almost speaks of THTX's doubt that they will be accepted. I mean, if they were confident about them they would broadcast it far and wide.
-LT